Home

Johnson & Johnson (JNJ)

188.64
+2.66 (1.43%)
NYSE · Last Trade: Oct 4th, 3:05 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close185.98
Open187.06
Bid187.28
Ask189.51
Day's Range186.91 - 189.78
52 Week Range140.68 - 189.78
Volume9,023,521
Market Cap495.87B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield5.200 (2.76%)
1 Month Average Volume8,764,893

Chart

About Johnson & Johnson (JNJ)

Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More

News & Press Releases

US Government Shutdown Casts Global Shadow: Economic Data Delays Fuel Investor Uncertainty
The United States government is currently in the throes of a shutdown, commencing at 12:01 a.m. EDT on October 1, 2025, after a congressional impasse prevented the passage of appropriations legislation for the 2026 fiscal year. This fiscal stalemate has immediately plunged global financial markets into a state
Via MarketMinute · October 3, 2025
Healthcare Stands Strong: A Pillar in the S&P 500 Amidst Tech Sector Retreat
As the S&P 500 navigates a dynamic market on October 3, 2025, the Healthcare sector has emerged as a steadfast performer, demonstrating remarkable resilience and contributing significantly to the overall market's strength. This stability comes at a crucial time, as the technology sector experiences a notable pullback, leading investors
Via MarketMinute · October 3, 2025
Data Blackout: Government Shutdown Leaves Fed Flying Blind Amidst Economic Crossroads
The U.S. economy finds itself at a critical juncture, navigating persistent inflation and a cooling labor market, while simultaneously grappling with the immediate and profound implications of an ongoing government shutdown. As of October 3, 2025, the federal government remains unfunded, triggering a widespread data blackout that has delayed
Via MarketMinute · October 3, 2025
Johnson & Johnson's Options Frenzy: What You Need to Knowbenzinga.com
Via Benzinga · October 3, 2025
Coinbase To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Fridaybenzinga.com
Via Benzinga · October 3, 2025
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Fridaybenzinga.com
Via Benzinga · October 3, 2025
Federal Shutdown Stalls Inflation Data, Blurring Fed's Path and Rattling Markets
A federal government shutdown has once again cast a shadow over the U.S. financial landscape, leading to an indefinite delay in the publication of critical U.S. inflation data. This unexpected halt in economic reporting presents significant challenges for the Federal Reserve's monetary policy decisions, as policymakers are left
Via MarketMinute · October 2, 2025
Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Via MarketMinute · October 2, 2025
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheapbenzinga.com
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via Benzinga · October 2, 2025
Vanguard Sounds Alarm: Is the US Stock Market 'Priced for Perfection'?
Vanguard, one of the world's largest investment management firms, has issued a stark warning regarding the U.S. stock market, cautioning that it is currently "priced for perfection." This assessment suggests that current equity valuations are overly optimistic, leaving little room for error and significantly increasing the potential for a
Via MarketMinute · October 2, 2025
Nanobiotix Stock Soars on Breakthrough Esophageal Cancer Data, Igniting Biotech Hopes
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed
Via MarketMinute · October 2, 2025
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented ability to design synthetic proteins for genome editing that not only match but significantly outperform their naturally occurring counterparts. This pivotal development, highlighted by recent research, signals a [...]
Via TokenRing AI · October 2, 2025
Tesla Stock Surges Nearly 2% In Thursday Pre-Market: What's Going On?benzinga.com
Tesla Inc. stock climbed 1.86% during Thursday pre-market trading session after CEO Elon Musk reached an unprecedented financial milestone.
Via Benzinga · October 2, 2025
Elon Musk Becomes First Person Worth $500 Billion, Tesla CEO's Wealth Is Now Larger Than Palantir, Alibababenzinga.com
Elon Musk has become the first person in history worth $500 billion, a fortune fueled by Tesla's stock surge, SpaceX's $400 billion valuation, and the rising value of his AI venture xAI Holdings.
Via Benzinga · October 1, 2025
US Government Shutdown Rocks Global Markets: A Deep Dive into the Economic Aftershocks
Washington D.C., October 1, 2025 – The United States federal government has officially entered a shutdown today, marking the first such funding lapse in nearly seven years and sending immediate ripples of uncertainty across global financial markets. The inability of Congress to pass appropriations legislation for the 2026 fiscal year
Via MarketMinute · October 1, 2025
Federal Reserve Navigates Treacherous Waters: Rate Cut Hopes Clouded by Data Blackout Amidst Government Shutdown
As October 1, 2025 dawns, the Federal Reserve finds itself ensnared in a complex economic predicament, grappling with the urgent need to stimulate a faltering labor market while simultaneously battling stubbornly high inflation. This delicate balancing act has been severely complicated by a federal government shutdown, which has effectively cut
Via MarketMinute · October 1, 2025
US Government Shutdown Ignites Market Volatility and Economic Uncertainty
As the United States government enters a shutdown as of October 1, 2025, financial markets are bracing for a fresh wave of economic uncertainty and volatility. This immediate "risk-off" environment has seen an initial dip in stock futures and a sell-off in the broader market, though historical data suggests the
Via MarketMinute · October 1, 2025
Should You Buy Kenvue Stock After Its 30% Plunge?fool.com
There hasn't been much good news lately for this Johnson & Johnson spinoff.
Via The Motley Fool · October 1, 2025
Stock Market Today: Pfizer Rallies on Trump Drug Pricing Deal and U.S. Investment Pledgefool.com
Pfizer surged after striking a landmark agreement with the Trump administration to lower drug prices and expand U.S. production.
Via The Motley Fool · September 30, 2025
Global Markets Defy Headwinds: Resilient Sentiment Prevails Despite Shutdown Fears
As the third quarter of 2025 drew to a close on September 30, global financial markets demonstrated a remarkable display of resilience, largely shrugging off significant geopolitical uncertainties and the imminent threat of a U.S. federal government shutdown. Major U.S. indices, including the Dow Jones Industrial Average (NYSE:
Via MarketMinute · September 30, 2025
Government Shutdown Looms: Goolsbee Warns of Blind Spots for Fed Rate Decisions
Chicago, IL – September 30, 2025 – As the specter of a U.S. government shutdown hangs heavy over Washington, Chicago Federal Reserve President Austan Goolsbee has issued a stark warning: such an event could severely hamper the central bank's ability to make informed monetary policy decisions, potentially delaying future interest rate
Via MarketMinute · September 30, 2025
Jobs Report Hangs in the Balance as Government Shutdown Looms
Washington D.C. – September 30, 2025 – The financial markets are bracing for significant turbulence as the specter of a government shutdown once again threatens to disrupt the flow of crucial economic data, most notably the highly anticipated monthly jobs report. With Congress deadlocked over budget negotiations, the potential halt in
Via MarketMinute · September 30, 2025
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Via MarketMinute · September 30, 2025
Healthcare Staffing Giant AMN Healthcare Soars Amidst Landmark Drug-Pricing Agreement
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a broader market optimism rippling through the healthcare sector. While AMN's direct stock drivers often stem from company-specific operational successes, today's surge
Via MarketMinute · September 30, 2025
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing agreement reached between the White House and a major pharmaceutical player, Pfizer (NYSE: PFE). This development has been widely interpreted by investors as
Via MarketMinute · September 30, 2025